Earlier this month, Congress approved, and President Obama signed, the Cures Act, formally known as the 21st Century Cures Act. Along with scores of other voluntary health and research organizations, the Parkinson’s Disease Foundation (PDF) applauds this move as one that will confront diseases head-on and accelerate research seeking cures. In this decisive, bipartisan move — too rare in these politically-divided days — the federal government has signaled its confidence that science can help us deliver on the elusive dream of drawing the curtain on diseases including Parkinson’s.
“I asked one of the best doctors I have seen — and I have worked with a few — about the effect, if any, of menopause on Parkinson’s disease. Her response was ‘estrogen doesn’t cause Parkinson’s disease,’ which wasn’t my question at all. What I remember about her answer was wondering: where can I turn for a better one?” It is striking just how similar Lisa Cone’s comments are to those of 25 other women who joined the Parkinson’s Disease Foundation (PDF) last month in launching our Women and PD Initiative, the first national coordinated effort to improve the health… Read More
If you have read the cover article in the Fall 2015 issue of our newsletter, News & Review, you already know that PDF has created a strategic plan to strengthen and accelerate our fight to advance the cure, and care, of Parkinson’s disease. As I enter my 20th anniversary year as chief executive officer of the Parkinson’s Disease Foundation, the new plan is both sobering and exciting.
Which question about Parkinson’s is your priority for scientists to answer? According to Cindy Bittker, M.S.W., a PDF Research Advocate from Hull, MA, the answer is: dystonia. As part of its Second Annual Community Choice Research Awards (open during April), PDF is profiling members of the PD community who have taken our survey to find out the priorities they suggest for scientists. The survey — open to people with PD and care partners until Thursday, April 30 — asks what is most important for researchers to study regarding specific aspects of the disease, including its symptoms, day-to-day management and treatment. Later in… Read More
Last month, it was announced that two new drugs were approved by the US Food and Drug Administration, for treatment of Parkinson’s disease (PD). Both drugs, Rytary™ and Duopa™, are updates to carbidopa/levodopa. They offer, respectively, a newer formulation and delivery method to reduce off-times for those with PD. In this Q&A, PDF speaks with Myra Hirschhorn, one of our trained Research Advocates, to understand the community reaction to the approvals. As part of the Parkinson’s Advocates in Research program, Myra has been trained in the drug development process, and educates her community about research.
When 30,000 neuroscientists gather together to talk about the brain, what can we learn about Parkinson’s disease? Our team found out at the latest meeting of the Society for Neuroscience (SfN) meeting in Washington, DC, which took place in November. At the meeting, PDF’s James Beck, Ph.D., VP for Scientific Affairs, and Beth Vernaleo, Ph.D., Senior Manager, Research Programs, were joined by PDF Research Advocates Todd Hebb and Paul Zimmet, D.D.S., both of whom live with PD. (Drs. Zimmet and Vernaleo are pictured inset).